Ulrich Storz
Senior Partner Michalski · Hüttermann & Partner Patent Attorneys
Ulrich Storz received his doctorate from the University of Münster in 2002 with a thesis in the field of neurobiology.
His is a chartered German patent attorney, a representative before the European Patent Office, and admitted to litigate before the Unitary Patent Court
Ulrich’s main areas of practice are the prosecution and enforcement of patent applications and patents as well as the preparation of freedom-to-operate analyses and expert opinions. He also advises on patent strategy issues, in particular in the life sciences sector (biotechnology, biophysics, biochemistry and microbiology), especially in the field of therapeutic antibodies and derivatives (bispecifics, CAR T cells and Antibody drug conjugates).
He also has extensive experience in gene editing technologies including CRISPR, TALEN and ZFN, and also works in the fields of stem cell technologies, plant biotechnology and enzymes.
Ulrich is regularly involved in major antibody opposition proceedings before the European Patent Office.
In addition, in recent years, he has supported a large number of extensive due diligence projects in the pharmaceutical/life sciences sector with volumes of between 500,000 and 1,2 billion euros.
Seminars
In today’s increasingly crowded ADC landscape, savvy IP strategy is critical for commercial success. This workshop explores how innovators can identify the IP opportunities and risks when developing a novel conjugate asset. Gain practical insights into competitive IP positioning, covering the type and timing of your own IP creation, as well as how to manage freedom-to-operate challenges. The workshop will demonstrate how to use IP strategy to enable your ADC or conjugate asset to reach its full commercial potential.
Key Questions:
- Reviewing approaches for leveraging known technology to minimise patent infringement risk
- Understanding the risks and opportunities of using known technology as the starting point for innovation
- Exploring strategies for protecting novel ADC assets and position them to withstand competitive challenges